Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-resistant Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Sep 8

PMID 22957061

Citations 40

Authors

Praveenkumar K Shetty

Sanjay I Thamake

Swati Biswas

Sonny L Johansson

Jamboor K Vishwanatha

Affiliations

Soon will be listed here.

Abstract

Alternative survival pathways are commonly seen to be upregulated upon inhibition of receptor tyrosine kinases (RTK), including Her-2. It is established that treatment with Herceptin leads to selective overexpression and activation of epidermal growth factor receptor (EGFR) and Src which further contributes to oncogenesis in Herceptin resistant and triple negative breast cancer (TNBC) patients. Here, we show a co-regulated upregulation in the expression of Annexin A2 (AnxA2), a known substrate of Src and one of the regulators of EGFR receptor endocytosis, in Herceptin resistant and Her-2 negative breast cancer. Immunohistochemical expression analysis revealed a reciprocal regulation between Her-2 and AnxA2 in breast cancer clinical samples as well as in cell lines as confirmed by protein and RNA analysis. The siRNA and Herceptin mediated downregulation/inhibition of Her-2 in Her-2 amplified cells induced AnxA2 expression and membrane translocation. In this study we report a possible involvement of AnxA2 in maintaining constitutively activated EGFR downstream signaling intermediates and hence in cell proliferation, migration and viability. This effect was consistent in Herceptin resistant JIMT-1 cells as well as in Her-2 negative breast cancer. The siRNA mediated AnxA2 downregulation leads to increased apoptosis, decreased cell viability and migration. Our studies further indicate the role of AnxA2 in EGFR-Src membrane bound signaling complex and ligand induced activation of downstream signaling pathways. Targeting this AnxA2 dependent positive regulation of EGFR signaling cascade may be of therapeutic value in Her-2 negative breast cancer.

Citing Articles

Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.

Weijie S Discov Oncol. 2024; 15(1):783.

PMID: 39692932 PMC: 11655786. DOI: 10.1007/s12672-024-01693-8.

Annexin A2 in Tumors of the Gastrointestinal Tract, Liver, and Pancreas.

Christofidis K, Pergaris A, Fioretzaki R, Charalampakis N, Kapetanakis E, Kavantzas N Cancers (Basel). 2024; 16(22).

PMID: 39594718 PMC: 11592865. DOI: 10.3390/cancers16223764.

Targeting AnxA2-EGFR signaling: hydroxychloroquine as a therapeutic strategy for bleomycin-induced pulmonary fibrosis.

Sangamesh V, Alagundagi D, Jayaswamy P, Kuriakose N, Shetty P Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):2015-2026.

PMID: 39222243 DOI: 10.1007/s00210-024-03417-9.

Interactions and conformational changes of annexin A2/p11 heterotetramer models on a membrane: a molecular dynamics study.

Lindsay S, Bartolotti L, Li Y J Biomol Struct Dyn. 2023; 42(19):10342-10351.

PMID: 37705315 PMC: 11611455. DOI: 10.1080/07391102.2023.2256877.

Pathobiological functions and clinical implications of annexin dysregulation in human cancers.

Prieto-Fernandez L, Menendez S, Otero-Rosales M, Montoro-Jimenez I, Hermida-Prado F, Garcia-Pedrero J Front Cell Dev Biol. 2022; 10:1009908.

PMID: 36247003 PMC: 9554710. DOI: 10.3389/fcell.2022.1009908.

References

Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A . Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene. 2003; 23(4):1010-3. DOI: 10.1038/sj.onc.1207200. View

Pinilla S, Honrado E, Hardisson D, Benitez J, Palacios J . Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat. 2006; 99(1):85-90. DOI: 10.1007/s10549-006-9184-1. View

Morel E, Gruenberg J . Annexin A2 binding to endosomes and functions in endosomal transport are regulated by tyrosine 23 phosphorylation. J Biol Chem. 2008; 284(3):1604-11. DOI: 10.1074/jbc.M806499200. View

Tan A, Swain S . Therapeutic strategies for triple-negative breast cancer. Cancer J. 2008; 14(6):343-51. DOI: 10.1097/PPO.0b013e31818d839b. View

Chuthapisith S, Layfield R, Kerr I, Hughes C, Eremin O . Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol. 2007; 30(6):1545-51. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Diaz V, Hurtado M, Thomson T, Reventos J, Paciucci R . Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004; 53(7):993-1000. PMC: 1774091. DOI: 10.1136/gut.2003.026831. View

Boyer J, Maxwell P, Longley D, Johnston P . 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004; 24(2A):417-23. View

Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C, Reedijk M . Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res. 2011; 71(1):277-86. DOI: 10.1158/0008-5472.CAN-10-2523. View

10.

Bhargava R, Gerald W, Li A, Pan Q, Lal P, Ladanyi M . EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005; 18(8):1027-33. DOI: 10.1038/modpathol.3800438. View

11.

Chuthapisith S, Bean B, Cowley G, Eremin J, Samphao S, Layfield R . Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer. 2009; 45(7):1274-1281. DOI: 10.1016/j.ejca.2008.12.026. View

12.

Rescher U, Gerke V . Annexins--unique membrane binding proteins with diverse functions. J Cell Sci. 2004; 117(Pt 13):2631-9. DOI: 10.1242/jcs.01245. View

13.

Valapala M, Thamake S, Vishwanatha J . A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci. 2011; 124(Pt 9):1453-64. PMC: 3078813. DOI: 10.1242/jcs.079236. View

14.

Zhao W, Chen G, Chen H, Pascale A, Ravindranath L, Quon M . Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. J Biol Chem. 2002; 278(6):4205-15. DOI: 10.1074/jbc.M210545200. View

15.

Biscardi J, Maa M, Tice D, Cox M, Leu T, Parsons S . c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274(12):8335-43. DOI: 10.1074/jbc.274.12.8335. View

16.

Donepudi M, Resh M . c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell Signal. 2008; 20(7):1359-67. PMC: 2459337. DOI: 10.1016/j.cellsig.2008.03.007. View

17.

Ling Q, Jacovina A, Deora A, Febbraio M, Simantov R, Silverstein R . Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004; 113(1):38-48. PMC: 300771. DOI: 10.1172/JCI19684. View

18.

Duncan R, Carpenter B, Main L, Telfer C, Murray G . Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2007; 98(2):426-33. PMC: 2361450. DOI: 10.1038/sj.bjc.6604128. View

19.

Choudhury A, Charo J, Parapuram S, Hunt R, Hunt D, Seliger B . Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer. 2003; 108(1):71-7. DOI: 10.1002/ijc.11497. View

20.

Valapala M, Vishwanatha J . Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011; 286(35):30911-30925. PMC: 3162451. DOI: 10.1074/jbc.M111.271155. View